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e under theAbstract Objectives: Trial registration has a great potential to increase research
transparency and public access to research results. This study examined the avail-
ability of results either in journal publications or in the trial registry from all studies
registered at ClinicalTrials.gov.
Methods: All 137,612 records from ClinicalTrials.gov in December 2012 were
merged with all 19,158 PubMed records containing registration numbers in the
indexing field or in the abstracts. A multivariate analysis was conducted to examine
the association between the availability of the results with study and participant
characteristics available in registration records.
Results: Fewer than 10% of the registered studies and 15% of the registered and
completed studies had published results. The highest publication rate of 22.4%
was for randomized trials completed between 2005 (starting year for structured
indexing in PubMed of study registration) and 2010. For 86% of overall and 78% of
completed registered studies, no results were available in ClinicalTrials.gov or in
journal publications. Studies funded by industry vs. other funding sources and drug
studies vs. all studies of other interventions were published less often after adjust-
ment for study type, subject characteristics, or posting of results in ClinicalTri-
als.gov.
Conclusion: Existing policy does not ensure availability of results from clinical
research. International policy revisions should charge principal investigators with
ensuring that the approved protocols and posted data elements are aligned and that
results are available from all conducted studies.
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Clinical research aims to inform clinical and policy
decision-making by providing valid evidence for
treatment benefits and harms [1–4]. However,
when conclusions about treatment benefits and
harms are based on incomplete evidence, biased
decisions and ineffective health care can result
[5]. Bias in the publication of studies that show
impressive results can exaggerate the benefits of
examined treatments [6–10].
Several policy initiatives have tried to improve
transparency and ensure wider availability of re-
sults from clinical research. The Food and Drug
Administration Modernization Act of 1997 required
that the NIH create a trial registry – ClinicalTri-
als.gov – for drug efficacy studies approved with
Investigational New Drug applications. In 2000,
the National Library of Medicine at the National
Institutes of Health launched ClinicalTrials.gov
and opened it to the public via the Internet, and
Congress mandated the registration of all clinical
trials of pharmacological treatments for serious
or life-threatening diseases at the ClinicalTri-
als.gov online database [11–14]. Then in 2005,
the International Committee of Medical Journal
Editors (ICMJE) and the World Association of Medi-
cal Editors made registration a condition of publi-
cation for all clinical studies [15]. Finally, the
International Clinical Trials Registry Platform (ICT-
RP) was developed to include 13 primary registries
which met the requirements of the ICMJE in provid-
ing 20 items with ‘‘the minimum amount of trial
information that must appear in a register in order
for a given trial to be considered fully registered’’
(see Supplementary Appendix 1, also available at
http://www.who.int/ictrp/network/trds/en/
index.html).
Ensuring the public access to the results from
clinical studies, the Food and Drug Administration
Amendments Act (FDAAA) of 2007 mandated post-
ing of the results from applicable clinical trials
(e.g., interventional, non-phase I trials of drugs
and devices subject to FDA regulation) on Clinical-
Trials.gov within 1 or 2 years of study completion
[16].
Nonetheless, publication of the results in journal
articles remains voluntary. Less than half of the
NIH-funded registered trials are published in a
peer-reviewed journal within 30 months of trial
completion [17]. Only 29% of completed registered
studies involving children and 53% of NIH-funded
trials have been published [18].
Previous research used time-consuming manual
searchers of the publications in various subsets ofregistered studies (i.e., by source of funding [17],
study participants [18], and specific health condi-
tions) [19]. In contrast, this paper examines result
availability from all studies registered with Clini-
calTrials.gov to answer the question: Do existing
policies in research registration, publication, and
indexing guarantee access to the results? This
study defines ‘‘availability of the results’’ as publi-
cation in the journals indexed on Medline or posting
the results with ClinicalTrials.gov
2. Methods
For this study, ClinicalTrials.gov registration re-
cords were linked with Medline publication records
by a unique registered study identifier (number of
clinical trial or NCT). First, all records of the regis-
tered studies with no time restriction were down-
loaded from ClinicalTrials.gov from February 2000
to December 2012 (Appendix 2). All 20 fields re-
quired by the ICMJE were downloaded. The fre-
quency of study types, design, funding,
participant characteristics, and posting of the re-
sults were analyzed relying on information pro-
vided by the investigators in registration records
[20]. Accuracy of the data in ClinicalTrials.gov
can be confirmed only by comparing the posted
data elements with those approved by the institu-
tional review boards, which was beyond the scope
of this study. For validation purposes, ambiguous
data (e.g., enrollment values of more than 99,999
participants or negative publication time intervals
when publications occurred before studies started
subject recruitment) were excluded from the vali-
dated analyses.
In contrast with the previous research focusing
on clinical trials only [21], all registered studies
were analyzed irrespective of study design, fund-
ing, subject characteristics or market status of
the examined treatments assuming that all clinical
research evidence is important for decision-making
(Appendix 2). The study design was categorized: as
randomized trial when the study design field men-
tioned random allocation of participants into the
treatment groups; as non-random studies when
investigators did not explicitly mention randomiza-
tion; and as unknown study design when investiga-
tors left this field blank. Interventions were
categorized as drug, procedure, radiation, biolo-
gics, or behavioral according to the categories in
ClinicalTrials.gov. Study findings were categorized
into two categories: industry funding category in-
cluded all studies funded by pharmaceutical or de-
vice companies exclusively or in combination with
individuals, universities, or community-based orga-
Publication bias 3nizations; all other funding sources category in-
cluded studies funded by the National Institutes
of Health or other U.S. Federal agencies exclu-
sively or in combination with industry funding, as
well as studies funded by individuals, universities,
or community-based organizations without any
industry involvement. The length of studies was
calculated as the time period between start and
completion dates. The publication time was esti-
mated as the time period between study comple-
tion and journal publication.
Medline publication records have unique study
registration numbers in a specifically designated
field with secondary study identification ([SI]) (de-
tailed information about indexing of the registered
studies is available in PubMed tutorial at http://
www.nlm.nih.gov/bsd/disted/pubmedtutorial/
020_810.html) [22]. In compliance with ICMJEs rec-
ommendations from 2005, all publications should
report a trial registration number in the article ab-
stract. Since the specific field for indexing of regis-
tered studies (secondary study identification field)
was introduced in 2005, Medline was searched for
registration numbers in that designated [SI] field,
but also in the article abstracts. A subgroup analysis
was then conducted among the studies registered
before and after 2005.
All retrieved references were imported into the
reference manager Endnote and then were ex-
ported to an Excel worksheet compatible with the
SAS statistical software.
When the article reported the results from more
than one registered study, additional reference re-
cords were created for each NCT. When a regis-
tered study was published in more than one
article, the fact of the publication was counted
only once using the earliest available publication.
For validation purposes, in order to determine
the accuracy of the Medline indexing of the regis-
tered studies (since some publications of the regis-
tered trials did not report study identification
numbers in abstracts but may have mentioned the
registration status in the full texts of the articles),
this study examined whether the secondary study
identification field identified all publications of
the registered studies in the core clinical journal
(Abridged Index Medicus list of core clinical jour-
nals is available in Appendix 3) that published the
greatest number of registered RCTs. To carry out
this task, trial registration numbers were searched
for in all Medline fields and in the full texts of the
articles published in that journal. If full text arti-
cles did not include study registration numbers, it
was concluded that the published study was not
registered [15].The publication records from PubMed were then
merged with the registration records from Clinical-
Trials.gov by the unique NCT number and the avail-
ability of the results and factors associated with
publication status were examined. Publication
rates were calculated as percentages of the regis-
tered studies with linked publication records in
PubMed. The percentages of the registered studies
were calculated with disposition of the results
within the trial registry. Speculative imputations
for missing data were avoided. Multivariate odds
ratios of publication were calculated by study type
(observational vs. interventional), random alloca-
tion of participants, recruitment as reported in
ClinicalTrials.gov, funding, examined interven-
tions, posting of the results in ClinicalTrials.gov,
and age and sex of enrolled participants. It was
hypothesized that odds of publications differ by
study funding, design, and examined interventions.
Subgroup analyses were conducted of the publica-
tion odds among registered completed or termi-
nated studies to test the hypothesis that
completed studies would have greater odds of pub-
lication. Publication odds may depend on the year
of study registration, for example, recently pub-
lished studies would have lower publication odds
compared with the studies registered more than
3 years ago. To address this issue survival analysis
was also conducted to examine publication of the
completed studies by study design and funding
[23]. The detailed analysis of the factors associ-
ated with posting the results in ClinicalTrials.gov
was beyond the scope of this study [24]. All hypoth-
eses testing at 95% CL were performed using SAS
9.3.
3. Results
A total of 137,612 registered studies were identi-
fied in ClinicalTrials.gov and 19,158 publications
of registered studies in PubMed in December 2012
(Fig. 1). After deleting duplicates and merging
the data from the trial registry with publication re-
cords from PubMed, 137,607 records of the regis-
tered studies and 12,938 publications of the
registered studies were included in the analyses
(analytical data file is available at https://net-
files.umn.edu/xythoswfs/webui/_xy-23709234_1-
t_xCJavcvC).
The studies were published in 1332 journals; 55%
of the studies were published in 32 journals. Each
of these 32 journals published more than 100 regis-
tered studies. The completed ‘‘Secondary Source
ID’’ field identified 97.3% of the publications of
the registered studies and 2.7% of the articles
Fig. 1 Study flow.
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articles but not in the ‘‘Secondary Source ID’’ field.
Only 9.4% of all registered studies and 15% of
registered and completed studies were published
(registration records in ClinicalTrials.gov could be
linked to publication records in Medline) (Table 1).
Publication rates differed by subject and study
characteristics (Table 1). The highest publication
rate of 22.4% was among the randomized trials
completed between 2005 and 2010 (Fig. 2). The
second highest publication rate of 22% was among
the registered studies with the results posted in
ClinicalTrials.gov. For the majority of registered
studies (86% overall and 78% of completed regis-
tered studies), no results were available in Clinical-
Trials.gov or in journal publications.
Multivariate analysis demonstrated that partici-
pant age and gender, interventional study design,
tested interventions, and industry funding were
associated with greater odds of publications. The
registered studies enrolling exclusively childrenpublished the results more often than the studies
of all ages had (Fig. 3). Registered studies that en-
rolled men and women or exclusively women pub-
lished results more often than studies that
enrolled exclusively men.
Interventional studies had greater odds of publi-
cation compared with observational studies. Ran-
domized trials had greater odds of publication
compared with nonrandomized studies. Studies
with results posted on ClinicalTrials.gov had great-
er odds of publication compared with the studies
without posting the results. The registered studies
examining drugs had lower odds of publication
compared with all other studies.
The studies funded by industry published results
less often compared with all other studies. The de-
scribed associations were significant irrespective of
the recruitment status (Fig. 3). Survival analysis
also demonstrated lower publication rates of indus-
try-funded studies (adjusted hazard rates ratio
0.87 95% CI 0.82–0.91) and the studies examining
Table 1 Publication status of registered studies.
Study categories (as
reported in ClinicalTrials.gov)
Study characteristics Unpublished Published/total (%)
Subject age Exclusively Children 7115 1087/8202(13.25)
All ages 117554 11851/129405(9.16)
Subject gender Both 105656 11177/116833(9.57)
Female 11945 1251/13196(9.48)
Male 6513 490/7003(7)
Examined interventions Drug 61142 6626/67768(9.78)
Non drugs 63527 6312/69839(9.04)
Study type Interventional 99936 11712/111648(10.49)
Observational 24126 1207/25333(4.76)
Study design Non randomized studies 58911 3382/62293(5.43)
Randomized controlled clinical trials 62136 9399/71535(13.14)
Not specified 3622 157/3779(4.15)
Posted the results on
ClinicalTrials.gov
Has results 6034 1658/7692(21.55)
No results available 118635 11280/129915(8.68)
The FDA definition of
the phases of clinical trials
Phase 0 785 39/824(4.73)
Phase 1 15182 813/15995(5.08)
Phase 1|Phase 2 5090 431/5521(7.81)
Phase 2 23511 2017/25528(7.9)
Phase 2|Phase 3 2474 432/2906(14.87)
Phase 3 16252 3402/19654(17.31)
Phase 4 12996 1783/14779(12.06)
Funding Industry funding 46757 4810/51567(9.33)
All other funding sources 77912 8128/86040(9.45)
Recruitment Active, not recruiting 14783 1695/16478(10.29)
Approved for marketing 33 4/37(10.81)
Available 81 2/83(2.41)
Completed 55311 9366/64677(14.48)
Enrolling by invitation 2084 86/2170(3.96)
No longer available 42 5/47(10.64)
Not yet recruiting 7110 76/7186(1.06)
Recruiting 35697 1290/36987(3.49)
Suspended 781 12/793(1.51)
Temporarily not available 19 0/19(0)
Terminated 6346 386/6732(5.73)
Withdrawn 1950 8/1958(0.41)
Withheld 432 8/440(1.82)
Expanded access 175 11/186(5.91)
Total Total 124669 12,938/137607(9.4)
Publication bias 5pharmacological treatments (adjusted hazard rates
ratio 0.94 95% CI 0.90–0.99).
This research examined whether study comple-
tion modified the association between funding
source and the publication. For instance, the stud-
ies funded by industry vs. not-for-profit sources
published results less often irrespective of the
recruitment status of both drug studies and all
combined nondrug studies (Table 2). However,
the type of the examined interventions modifiedthe association between funding source and publi-
cation. In fact, industry funding was associated
with lower rates of publication for all drug studies
and completed studies examining drugs, devices,
and procedures. Industry-funded genetic studies
published the results more often than the studies
with not-for-profit funding sources. The subject
allocation also modified the association between
funding source and publication. Industry funding
was associated with a lower rate of publication
Fig. 2 Percentage of published among registered studies by the year of completion. RCT – randomized controlled
clinical trials % published among all registered; % completed and published among all completed studies; % published
RCTs among all registered RCTs.
Age
Exclusively children vs. all  age groups in all registered studies 
Exclusively children vs. all  age groups in registered and completed  studies
Gender
Both genders vs. men in all registered studies 
Women vs. men in all registered studies 
Both genders vs. men in registered and completed  studies 
Women vs. men in registered and completed  studies 
Treatments
Drug interventions vs. all other interventions in all registered studies 
Drug interventions vs. all other interventions in registered and completed 
studies
Design
Randomized trials vs. non randomized studies in all registered studies 
Interventional vs. observational studies in all registered studies 
Randomized trials vs. non randomized studies in registered and completed  studies 
Interventional vs. observational studies in registered and completed  studies
Funding
Industry  vs. not for profit funding in all registered studies 
Industry  vs. not for profit funding in registered and completed 
studies
Posting of the results in clinicaltrials.gov
Studies with posted vs. not posted results in all registered studies 
Studies with posted vs. not posted results in registered and completed  studies
Comparison groups 
1.33 (1.24, 1.43)
1.43 (1.32, 1.55)
1.35 (1.23, 1.48)
1.32 (1.18, 1.47)
1.56 (1.40, 1.74)
1.53 (1.34, 1.74)
0.91 (0.87, 0.94)
0.87 (0.83, 0.92)
2.41 (2.29, 2.52)
1.28 (1.18, 1.37)
2.50 (2.36, 2.65)
1.46 (1.33, 1.61)
0.83 (0.79, 0.86)
0.70 (0.67, 0.74)
2.81 (2.64, 2.99)
1.92 (1.80, 2.05)
Adjusted odds ratios* (95% CI) 
0.4 1 3
Fig. 3 Publication of the studies registered in ClinicalTrials.gov studies. * Odds ratios were adjusted to all listed
variables: subject age, gender, randomized design, funding, intervention types, and posting of the results on
ClinicalTrials.gov.
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Table 2 Adjusted odds ratio of publication status by industry funding, examined interventions, and subject age.
Comparison groups Examined interventions Odds ratio
(lower 95%CI
to upper 95%CI)
Odds ratio
(lower 95%CI
to upper 95%CI)
All registered studies Completed studies
Industry funding vs. other Randomized trials 0.80(0.77 to 0.84) 0.64(0.60 to 0.67)
Non randomized studies 0.90(0.83 to 0.97) 0.93b(0.85 to 1.01)
Randomized trials of drugs 0.81(0.77 to 0.85) 0.66(0.62 to 0.70)
Randomized trials of non drug
interventions
0.86(0.80 to 0.92) 0.78(0.72 to 0.84)
Non randomized studies of drugs 0.86(0.80 to 0.92) 0.78(0.72 to 0.84)
Non randomized studies of non drug
interventions
0.81(0.77 to 0.85) 0.66(0.62 to 0.70)
Drug 0.83(0.78 to 0.87) 0.66(0.62 to 0.71)
All non drug interventions 0.84(0.78 to 0.89) 0.78(0.72 to 0.84)
Behavioral 1.13(0.81 to 1.56) 1.19(0.81 to 1.75)
Biological 1.00(0.86 to 1.15) 1.02(0.86 to 1.21)
Device 0.87(0.75 to 1.00) 0.73(0.61 to 0.87)
Dietary supplement 0.84(0.62 to 1.15) 0.71(0.50 to 1.00)
Drug 0.83(0.79 to 0.87) 0.67(0.63 to 0.71)
Genetic 2.51(1.29 to 4.87) 1.34(0.55 to 3.27)
Other 0.82(0.64 to 1.03) 0.63(0.48 to 0.84)
Procedure 0.82(0.65 to 1.02) 0.73(0.55 to 0.99)
Radiation 0.88(0.31 to 2.53) 0.99(0.21 to 4.74)
Adult vs. child Drug interventions 0.57(0.50 to 0.64) 0.69(0.61 to 0.79)
All non drug interventions 0.76(0.68 to 0.84) 0.47(0.40 to 0.54)
Adult vs. senior Drug interventions 0.53a(0.34 to 0.81) 0.74b(0.45 to 1.21)
All non drug interventions 0.78a(0.55 to 1.11) 0.39b(0.23 to 0.67)
Child vs. child adult Drug interventions 1.13a(0.96 to 1.33) 1.65b(1.37 to 2.00)
All non drug interventions 1.46a(1.27 to 1.69) 1.15b(0.95 to 1.40)
Child vs. senior Drug interventions 0.93(0.59 to 1.44) 1.06(0.65 to 1.75)
All non drug interventions 1.03(0.72 to 1.48) 0.84(0.49 to 1.44)
a Differences by intervention status among all studies.
b Differences by intervention status among completed studies.
Publication bias 7for randomized trials but not for nonrandomized
studies (Table 2).
Registered studies enrolling exclusively adults
vs. exclusively children or vs. exclusively seniors
had lower odds of publication irrespective of inter-
vention type and recruitment status (Table 2). The
odds of publication did not differ among registered
studies enrolling exclusively children vs. exclu-
sively seniors irrespective of intervention type or
recruitment status (Table 2).
Because of low publication rates, the results
were not available for 73% of the enrolled partici-
pants in the completed studies and for 75% of the
enrolled subjects in terminated studies (Table 3).
Thus, since many studies were not reported at
all, the results for more than 70% of the enrolled
participants are unknown. The time between study
start and completion was shorter for industry-funded (1.8 years) vs. other studies (3.1 years)
and for drug studies (2.2 years) vs. other interven-
tions (3 years) (data not shown). The time periods
between reporting of results in ClinicalTrials.gov
and study completion and study publication in Pub-
Med averaged around 2 years.
4. Discussion
Very low publication rates were found for studies
registered in ClinicalTrials.gov. For the majority
of registered studies (86% overall and 78% of com-
pleted registered studies), no results were avail-
able in ClinicalTrials.gov or in journal
publications. These results are in concordance with
previously published studies confirming that the re-
sults are not available for the public from the
majority of clinical research [17,21,25].
Table 3 Participant enrollment by recruitment and publication status.
Recruitment and publication status Suma Mean ± Standard deviation Maximum % Of total
Active, not recruiting 9766327 623 ± 3695 91000 16.83
Completed 24851854 415 ± 2531 98832 42.82
Enrolling by invitation 1825475 851 ± 3657 61864 3.15
No longer available 1000 1000 1000 0.002
Not yet recruiting 2791464 398 ± 2052 55000 4.81
Recruiting 17097671 470 ± 2552 89646 29.46
Suspended 191589 248 ± 913 12000 0.33
Terminated 1312538 201 ± 1211 50000 2.26
Withdrawn 203141 108 ± 569 10000 0.35
Completed and published 6711031 746 ± 3474 98832
Completed but unpublished 18140823 356 ± 2321 98483 73% of all completed
Terminated and published 333745 900 ± 3014 32867
Terminated and unpublished 978793 159 ± 989 50000 75% of all terminated
Total unpublished 47298465 401 ± 2462 98483
Total published 10742594 864 ± 3896 98832 18.51
a For validation purposes the studies with >99,999 were excluded.
8 T.A. Shamliyan, R.L. KaneThese results were compared with the existing
literature by the methods to detect publications
of the registered studies. When the researchers
searched for publications by the names of the prin-
cipal investigators, study titles, or examined drugs
in addition to registration numbers, they reported
similar (much less than 50%) or only slightly higher
publication rates [25,17]. When the researchers
found registration numbers in the full texts of the
articles retrieved for inclusion into systematic re-
views, the rates were similar to this study
[19,26]. These search findings could be affected
by poor compliance of the authors and journal edi-
tors with reporting registration of published manu-
scripts [17,27,28]. Reported differences in the
availability of the results from clinical research re-
flect several accountability gaps:
(1) The trial registry does not have a single field in
which to mark study applicability to the federal
law to post the results;
(2) Journal editors published unregistered trials or did
not require consistent reporting of the valid regis-
tration status in the abstracts;
(3) PubMed indexed trials without provided valid regis-
tration numbers.
The present study has limitations. No analysis
was performed as to whether journals adhered to
the policy of publishing only registered studies
[15]. Only one trial registry, ClinicalTrials.gov,
was analyzed since all U.S. studies should be regis-
tered in this registry [29]. Other registries do not
allow posting the results which makes result avail-
ability analysis difficult. The authors of the articles
were not contacted to request additional informa-tion about study registration [30]. Also, principal
investigators of the registered studies were not
contacted for additional information about study
enrollment or missing information. Actual publica-
tion bias was not analyzed by examining greater
odds of publication of the studies with favorable
statistically significant results [8], nor were devia-
tions from the protocols in the published articles
[31], or selective outcome reporting examined
[32]. It was not a goal of this study to compare pub-
lication rates by way of searching for publications
associated with each registered study, because to
do so would have been time-prohibitive and unfea-
sible for clinicians, healthcare consumers or policy
makers. Nonetheless, the straightforward search
methodology followed in this study should have re-
sulted in easy identification of publications of the
registered studies.
It was concluded that existing clinical research
policies do not guarantee availability of research
results in general. Odds of the publication also dif-
fered depending on participant age and gender as
well as study funding and design. Studies funded
by industry vs. other funding sources and drug stud-
ies vs. all other interventions were published less
often after adjustment for study type, subject
characteristics, or posting of results in ClinicalTri-
als.gov. Therefore, policy revisions should specifi-
cally address the studies with the lowest
publication rates, namely industry-funded drug
studies.
Several initiatives focus on improving result
availability from clinical studies. The recently pro-
posed Trial and Experimental Studies Transparency
(TEST) Act (H.R. 6272) would expand the manda-
Table 4 Proposed policy changes to ensure accountability of investigators for data integrity and availability of the sults [34,35]
Registration Consent form Study status R ults
Principal
investigators
Register protocols in
ClinicalTrials.gov as part
of the IRB application
Include study
registration number in
the consent form
Updating recruitment
status in
ClinicalTrials.gov
Po ting of study results in ClinicalTrials.gov,
in luding:
– Participant Flow
– Baseline Characteristics
– Outcome Measures
– Serious Adverse Events
– Other Adverse Events (expected and unexpected)Provid-
ing free access to the trial data
Institutional
Review Boards
(IRBS)
Approve enrollment for
registered protocols only
Approve consent form
with trial registration
number
Suspension of trials that
did not provide
complete and accurate
information about study
recruitment and
termination
Any changes in the
protocol or subject
enrollment must be
posted in
ClinicalTrials.gov
D ciplinary and financial actions against principal
in estigators who did not post the results in
C icalTrials.gov within 1 year after completion or
te mination of the trial
A uring a proper data de-identification for sharing
th results
Data Safety
Monitoring
Boards (DSMB)
Disclosure of safety
outcomes in
ClinicalTrials.gov
Disclosure of reasons for
termination or
suspension to
ClinicalTrials.gov
ClinicalTrials.gov Adding downloading
option for routine
monitoring fields for
exact reasons for
termination or
suspension of clinical
trials
C ating automated alerts for trials that did not post
th results within 1 year after completion or
te mination of the studies
In rming IRBs (via automated emails) about absent
or incomplete posting of the results from clinical
tr ls
In rming the NIH funding agencies (automated
emails) about absent or incomplete posting of the
re ults from the NIH funded trials
(continued on next page)
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Table 4 (continued)
Registration Consent form Study status Results
Crea ng automated
alert for trials that did
not u date recruitment
statu according to the
dates in the protocol
Infor ing IRBs
(auto ated emails)
abou incomplete
infor ation regarding
proto ols, recruitment
statu , and reasons for
trial completion by
princ al investigators
Informing the NIH
funding agencies
(automated emails)
about absent or
incomplete posting of
the results from the NIH
funded trials
NIH Funding Agencies Adding downloadable
field in the Research
Portfolio Online
Reporting Tools
(RePORT) grant
database with a
registration status and
registration
identification number
for all clinical trials
funded by the NIH
Disciplinary and financial
actions against principal
investigators who did
not post the results in
ClinicalTrials.gov within
1 year after completion
or termination of the
NIH funded trials
Stakeholders in the results of clinical research Participants are
informed about posted
protocols and plans to
post the results from
clinical trials.
Parti ipants are
infor ed about early
term ation or
suspe sion of the trials
Inves igators who
cond ct independent
analy is of reported
findin s can easily
analy e incompletion of
clinic l trials by the
topic of research,
treat ent, sponsor, or
subje t characteristics
Participants are
informed about posted
results from clinical
trials.
Investigators who
conduct independent
analysis of reported
findings can make valid
conclusions for informed
decision-making in
clinical settings
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Publication bias 11tory registration and results posting for all inter-
ventional studies of drugs or devices regardless of
study design, clinical trial phase, treatment mar-
keting status, or trial location [33]. Under TEST,
all American and foreign trials of the drugs or de-
vices marketed in the United States must be regis-
tered and the results must be posted in
ClinicalTrials.gov within 2 years after study com-
pletion (including trials of unapproved drugs or de-
vices) [33]. Under TEST, the investigators will be
required to post subject flow, baseline and post-
treatment outcomes, and adverse effects. In addi-
tion, TEST requires posting of the deposition of
consent and protocol documents approved by insti-
tutional review boards [33]. This legislation is
timely and important.
International AllTrials campaign (available at
http://www.alltrials.net) calls for registration
and results reporting for all clinical studies. Sharing
clinical research data is supported by the World
Health Organization (WHO), the US National Insti-
tutes of Health (NIH), the Cochrane collaboration,
the Institute of Medicine and other respected inter-
national organizations [34]. All clinical studies
should be registered before recruitment of the first
participant [18,35] in trial registries that comply
with the World Health Organization (WHO) mini-
mum dataset [36]. Trial registration should be
mandatory irrespective of trial phase or design,
study completion, foreign participant residency,
market status of the examined interventions, or
voluntary publication status [18,35,37,38].
Better coordination between the Office of Hu-
man Research Protection and the Office of Re-
search Integrity is necessary to guarantee human
subject protection and availability of the results.
Routine monitoring would be more efficient and
cost-effective with better harmonization and con-
sistent use of unique study identification numbers
across all databases—including ClinicalTrials.gov,
Medline, the NIH grant database, and the FDA data-
base. TEST legislation should require: (1) registra-
tion of all human trials as a condition of
enrollment approval by institutional review boards;
(2) validation of the provided information; and (3)
accountability of sponsors for complete, accurate,
and timely updated information. Continuous har-
monization between IRB electronic databases with
approved protocols with the trial registry would
preclude subject enrollment in unregistered stud-
ies and thus guarantee a registration of all human
trials.
Potential trial participants should be advised to
participate only in registered studies with publiclyavailable protocols and written assurance of the
result availability [39].
Modern information technologies enable inex-
pensive and effective monitoring of compliance
with the policy as well as availability of the results.
Trial registries should have analyzable fields for
trial completeness, applicability to FDA regula-
tions, enrollment status, and exact reasons for ter-
mination. Automated alerts could be used to
inform principal investigators, institutional review
boards, and regulatory agencies about deadlines
to comply with policy, enrollment status, and
availability of the results.
Principal investigators and sponsors should be
accountable for data integrity during registration
and publication processes (Table 4) [35]. This study
could not explain why some publications included
NCTs that never actually existed, or why the
recruitment status was omitted or different in
the published articles compared with the protocols
posted in ClinicalTrials.gov [35].
Poor publication rates of the registered studies
demonstrate a need for revisions in clinical re-
search policy in order to guarantee availability of
the results [33]. It points to some serious deficien-
cies in the current research enterprise that threat-
ens the societal goal of evidence-based practice
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